Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 58   

Articles published

ARNA 4.04 0.00 (0.00%)
price chart
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Vivus, Arena shares jump on insurance coverage for diet pills
Health insurer Aetna Inc (AET.N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up. The decision by the third-largest health insurer to provide coverage ...
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Prescription drug deaths: Two stories
Pete Jackson attended his brother-in-law's funeral along with his daughter, Emily, six years ago. He never dreamed it would be the last day of his daughter's life.
Cardinals' TV ratings continue slide
The Cardinals have had big runs in each of the past two seasons, their miraculous comeback in 2011 from being 10� games out of a playoff spot in late August to winning the World Series, then gaining the final wild-card slot this season.
Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)
Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the October 15 and October 31 settlement dates.
FSD Drugs Advance as Women Push for Equal Access
In July, investors raised $20 million for startup Sprout Pharmaceuticals, which hopes to succeed where Boehringer Ingelheim failed by bringing flibanserin through development phases to market.
Amgen Therapy Slims Monkeys as Study Seeks Obesity Drug
Nov. 28 (Bloomberg) -- An antibody discovered by Amgen Inc. researchers reduces weight and increases glucose tolerance in monkeys, according to a study, potentially opening up a new approach for treating obesity and diabetes in humans.
Indian board rejects AstraZeneca's patent plea on cancer drug
Natco and another domestic drugmaker, G. M. Pharma, had opposed the initial patent application for AstraZeneca quinazoline derivative.
Covington's miracle man: How Chuck Scheper worked to save his city (Video)
Northern Kentucky's largest city had just lost two major employers - Omnicare Inc. and Nielsen - and the $1.2 million in payroll taxes they generated.
The Wild October Ride Of Vivus
Right now only two entries have received FDA approval - Qysmia (formerly called Qnexa) from Vivus and Belviq from rival Arena Pharmaceuticals (NASDAQ:ARNA). Back in February the ... approved at this time. The company is going to appeal the decision.